Cotización Kura Oncology - KURA

Herramientas de nivel profesional para inversores individuales.

Premium

Último Precio

14.25

Postura de Compra

13.72

Postura de Venta

14.25

Volume Operado de la Acción

925,654

15.42 Rango del Día 16.09

9.06 Rango de 52 semanas 24.17

Capitalización de Mercado [m]

1.108B

Precio Anterior

15.96

Precio de Apertura

15.96

Hora

702

14.25

(formt)

Última hora de negociación

Volumen financiero

US$ 14,632,028

Precio Promedio Ponderado

15.8072

Volumen promedio (3 m)

597,348

Acciones en circulación

77,763,750

Rendimiento del Dividendo

Ratio Precio/Utilidad

-8.11

Beneficio por acción (BPA)

-1.96

turnover

Beneficio neto

-152.63M

Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progressi... Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has a lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States. Mostrar más

Sector

Pharmaceutical Preparations

Industria

Blank Checks

Sitio web

www.kuraoncology.com

Sede

Wilmington, Delaware, USA

Fundado

2015

Kura Oncology Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker KURA. The last closing price for Kura Oncology was US$15.96. Over the last year, Kura Oncology shares have traded in a share price range of US$ 9.06 to US$ 24.17.

Kura Oncology currently has 77,763,750 shares in issue. The market capitalisation of Kura Oncology is US$1.24 billion. Kura Oncology has a price to earnings ratio (PE ratio) of -8.11.

Form 8-K - Current report

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias PR Newswire SAN DIEGO and TOKYO, Nov. 20, 2024 – Kura to receive a...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	-4.38	-23.5104669887	18.63	19.25	13	857856	16.46985262	CS
4	-3.02	-17.4869716271	17.27	19.7283	13	848072	17.36361526	CS
12	-5.93	-29.3855302279	20.18	21.569	13	597348	18.37208304	CS
26	-7.86	-35.5495251018	22.11	23.48	13	628907	19.61565502	CS
52	4.68	48.9028213166	9.57	24.17	9.06	903000	18.648039	CS
156	-2.86	-16.715371128	17.11	24.17	7.41	841393	15.06208692	CS
260	-0.62	-4.16946872898	14.87	42.82	6.34	747474	17.8494029	CS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
FBRXForte Biosciences Inc	US$ 13.60 (129.53%)	28.92M
QSIQuantum Si Inc	US$ 1.39 (119.59%)	279.33M
XCURExicure Inc	US$ 11.01 (89.18%)	22.91M
AGFYAgrify Corporation	US$ 37.4635 (68.00%)	921.45k
SLXNSilexion Therapeutics Corporation	US$ 0.3495 (54.51%)	198.66M
SKKSKK Holdings Limited	US$ 4.55 (-47.28%)	816.93k
QMMMQMMM Holdings Limited	US$ 0.713999 (-43.78%)	4.61M
XTKGX3 Holdings Company Ltd	US$ 0.0901 (-37.82%)	5.95M
PRFXPainReform Ltd	US$ 1.02 (-27.14%)	5.09M
GLEGlobal Engine Group Holding Ltd	US$ 3.81 (-26.59%)	230.23k
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.191 (17.39%)	662.68M
DBGIDigital Brands Group Inc	US$ 0.1345 (15.35%)	326.45M
NVDANVIDIA Corporation	US$ 145.89 (-0.76%)	309.57M
QSIQuantum Si Inc	US$ 1.39 (119.59%)	283.09M
SLXNSilexion Therapeutics Corporation	US$ 0.3495 (54.51%)	200.06M